Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.

The Journal of infectious diseases - 14 Feb 2024

Chou Sunwen, Alain Sophie, Cervera Carlos, Chemaly Roy F, Kotton Camille N, Lundgren Jens, Papanicolaou Genovefa A, Pereira Marcus R, Wu Jingyang J, Murray Rose Ann, Buss Neil E, Fournier Martha

Abstract excerpt

BACKGROUND: This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders). METHODS: Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54, and UL27. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytomegalovirus

Share to Cytomegalovirus Infections

Share to Drug Resistance, Viral

Share to Ganciclovir

Share to Phosphotransferases (Alcohol Group Acceptor)

Share to Transplant Recipients

Source

Open in PubMed Open full text

Identifiers

PMID: 37506264
DOI: 10.1093/infdis/jiad293
PMCID: PMC10873177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.PMID 37506264Read ↗

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.Semantic proximity Read ↗

Approach to drug-resistant cytomegalovirus in transplant recipients.Semantic proximity Read ↗

Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients.Semantic proximity Read ↗

Maribavir use in practice for cytomegalovirus infection in French transplantation centers.Semantic proximity Read ↗

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.Semantic proximity Read ↗

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infectionSemantic proximity Read ↗

The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies.Semantic proximity Read ↗

Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.Semantic proximity Read ↗

Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance.Semantic proximity Read ↗

The biology of cytomegalovirus drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.